Hartmut Juhl

Prof. Dr. Hartmut Juhl is an entrepreneur, surgical oncologist, and world-renowned researcher dedicated to the science of tissue quality and its application to precision medicine in cancer diagnostics and therapeutics. He founded Indivumed to decipher the complexity of cancer and to enable truly personalized medicine.

Hartmut’s career started with studying medicine at the Hamburg-Eppendorf University Clinic from 1979 to 1986. He received his doctorate of medicine (Dr. med.) in 1989 and his “Habilitation” in Surgical Oncology in 1996.

Hartmut holds a professorship at the Medical Faculty of Hamburg University, is an adjunct professor at the Lombardi Cancer Center of Georgetown University, and has served as an advisor to the U.S. National Cancer Institute on matters of tissue quality for clinical and research applications.

He has led Indivumed since 2002 with a visionary entrepreneurial spirit. For this, he has received several awards of recognition.

For founding Indivumed GmbH in Hamburg he was awarded the Hamburg Foundation Prize in the category of “Founders of new Businesses” in 2003, as well as the German Foundation Prize in the category of “New Visionary” in 2005.

Together with scientists from Johns Hopkins University, Baltimore, Maryland, Hartmut participated in defining the first Liquid Biopsy technology to analyze circulation tumor DNA in plasma samples. For that, the AACR awarded Hartmut as part of the international multidisciplinary team for the concept of “liquid biopsies” for cancer, which has led to dramatic technological advancements in detecting cancer and has defined a new field in oncology.

Being first in commercializing this technology, Hartmut co-founded Inostics GmbH in 2008, as a subsidiary of Indivumed GmbH, jointly owned with scientists from Johns Hopkins University. Inostics was sold to Sysmex Corp. only three years after its foundation.

Since 2002, Hartmut has been leading the company with a clear vision – every step financially and strategically taken, from the beginning to now, from extending the advanced IndivuServ products and services to building IndivuType, the deepest oncology multi-omics database available today and IndivuTest, directly serving patients and oncologists with scientific data for better therapy selection. All this with the goal of realizing truly personalized medicine in mind.